Hybrid Quantum System Models Protein Reaction Energy
The processor helps resolve energy barriers in ADGRG1 autoproteolysis, potentially accelerating future drug target research.
Updated on Oct. 21, 2026 in Quantum Computing
Live Poll
Do you believe advanced quantum simulations will improve our ability to treat complex diseases?
Researchers have successfully simulated the complex autoproteolysis of the ADGRG1 protein using a hybrid system of a 54-qubit quantum processor and 1,200 NVIDIA H100 GPUs. This research-stage study resolves previous modeling discrepancies by establishing a new calculated energy barrier for the reaction.
Why it matters
Adhesion GPCRs, including ADGRG1, remain notoriously difficult drug targets due to the scale of the quantum-mechanical processes involved in their function. This hybrid approach demonstrates a path to mapping biological processes that exceed the limits of traditional classical supercomputing.
The simulation mapped 26 electrons and orbitals onto 52 qubits of an IQM 54-qubit processor, collecting one million measurements per structure. Classical computations were performed on the Wolpertinger cluster at the Leibniz Supercomputing Centre.
The players
IQM
A quantum hardware developer specializing in superconducting qubit processors used for hybrid computing research.
NVIDIA
A leader in accelerated computing hardware, providing the H100 GPU architecture used for high-performance classical simulations.
Leibniz Supercomputing Centre
A major European high-performance computing facility that hosted the classical cluster used in this multiscale simulation.
The details
The team utilized a multiscale pipeline that facilitates the exchange of geometries, Hamiltonians—the mathematical operators representing the total energy of the system—and measurement data between quantum and classical architectures. By employing an iterative version of quantum-selected configuration interaction, the researchers sampled previously overlooked configurations of the ADGRG1 receptor that are essential to understanding its autoproteolysis mechanism.
Timeline
The research was published in 2026.
The Tech Race
This study represents a significant milestone in applying NISQ-era quantum hardware to solve long-standing biological modeling challenges. It follows the broader trend of integrating quantum processors with classical GPU clusters to address chemical reactions that were previously computationally intractable.
This development is currently in the research stage and does not yet impact clinical treatments for patients with ADGRG1-related conditions. The modular pipeline design is intended to enable future researchers to refine quantum algorithms for broader applications in drug discovery.
The takeaway
This hybrid simulation confirms that quantum-assisted modeling can resolve energy barriers that hinder pharmaceutical development for complex proteins. Future milestones to watch include the integration of more advanced embedding schemes that could allow researchers to model increasingly larger molecular systems.
Further reading
For more on the current state of hybrid processing, see our coverage of Quantum Computing.
Source note: This article includes information reported by Quantum Zeitgeist.
Live Poll
Do you believe advanced quantum simulations will improve our ability to treat complex diseases?
